Smart drugs: tyrosine kinase inhibitors in cancer therapy.
摘要：
Cancer therapy directed at specific, frequently occurring molecular alterations in signaling pathways of cancer cells has been validated through the clinical development and regulatory approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumors. While most novel, target-directed cancer drugs have pregenomic origins, one can anticipate a postgenomic wave of sophisticated "smart drugs" to fundamentally change the treatment of all cancers. With these prospects, interest in this new class of therapeutics extends from basic research scientists to practicing oncologists and their patients. An extension of the initial successes in molecular oncology will occur more quickly and successfully through an appreciation of lessons learned with the first group of agents in their progress through clinical development.
展开
关键词：
Animals Humans Receptor, Epidermal Growth Factor Receptor, erbB-2 Receptors, Vascular Endothelial Growth Factor Antineoplastic Agents Receptors, Growth Factor Fusion Proteins, bcr-abl Enzyme Inhibitors Drug Delivery Systems
DOI：
10.1016/S1535-6108(02)00039-9
被引量：
年份：
2002
Elsevier
Elsevier
(全网免费下载)
Semantic Scholar
万方医学
dx.doi.org
查看更多
Ingenta
Cell Press
NCBI
NCBI
Europe PMC
BioMed Central
ResearchGate
(全网免费下载)
ResearchGate
EBSCO
pubman.mpdl.mpg.de
yadda.icm.edu.pl
(全网免费下载)
www.socolar.com
molecular-cancer.com
scienceopen.com
journal-of-hepatology.eu
intl-jpet.aspetjournals.org
mct.aacrjournals.org
annclinlabsci.org
core.ac.uk
mysciencework.com
mcponline.org
core.ac.uk
(全网免费下载)
pubfacts.com
deepdyve.com
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
